Terlipressin Acetate

醋酸特利加压素

Report date: 2023/08/23 16:41:23
NME

Base Information

Drug NameTerlipressin Acetate
Drug Alias NameterlipressinumterlipresinaterlipressineGlycylpressinGlypressine +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin receptor agonists
TargetsVasopressin receptor
Therapy Area/IndicationsDecompensated Liver CirrhosisDrug-Related Side Effects and Adverse ReactionsShock +[10] 
Global Approved IndicationsHemorrhageHepatorenal Syndrome
Approved Indications in ChinaHemorrhage
Original Approved Country/TerritoryUnited Kingdom
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesThailand +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBiovie Inc
China Registration ClassN/A

Develop Information

Active CompaniesFerring GmbhPostgraduate Institute Of Medical Education And ResearchInstitute Of Liver And Biliary Sciences, India +[7] 
Inactive CompaniesUniversity of ZurichFerring BvMallinckrodt +[8] 
Active IndicationsDrug-Related Side Effects and Adverse ReactionsShockHemorrhage +[6] 
Inactive IndicationsDecompensated Liver CirrhosisAscitesRenal Insufficiency +[4] 

Other Information

ATC CodeH01BA04
Related LinksWikipediaDrugBankKEGG